GlaxoSmithKline (GSKN) Ratios
GlaxoSmithKline Ratios
MX:GSKN's free cash flow for Q3 2026 was $2.41B. For the 2026 fiscal year, MX:GSKN's free cash flow was decreased by $-372.39M and operating cash flow was $2.79B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.82 | 0.78 | 0.88 | 0.91 | 0.79 |
| Quick Ratio | 0.54 | 0.52 | 0.62 | 0.68 | 0.54 |
| Cash Ratio | 0.16 | 0.17 | 0.14 | 0.16 | 0.18 |
| Solvency Ratio | 0.18 | 0.11 | 0.12 | 0.34 | 0.08 |
| Operating Cash Flow Ratio | 0.33 | 0.30 | 0.29 | 0.36 | 0.25 |
| Short-Term Operating Cash Flow Coverage | 2.38 | 3.01 | 2.20 | 2.16 | 1.63 |
| Net Current Asset Value | $ -27.54B | $ -29.38B | $ -35.14B | $ -29.28B | $ -52.94B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.29 | 0.29 | 0.31 | 0.35 | 0.31 |
| Debt-to-Equity Ratio | 1.08 | 1.24 | 1.35 | 1.98 | 1.61 |
| Debt-to-Capital Ratio | 0.52 | 0.55 | 0.57 | 0.66 | 0.62 |
| Long-Term Debt-to-Capital Ratio | 0.47 | 0.50 | 0.51 | 0.60 | 0.57 |
| Financial Leverage Ratio | 3.73 | 4.35 | 4.42 | 5.68 | 5.25 |
| Debt Service Coverage Ratio | 2.52 | 2.16 | 1.91 | 1.70 | 1.13 |
| Interest Coverage Ratio | 12.14 | 6.11 | 8.70 | 7.52 | 5.56 |
| Debt to Market Cap | 0.24 | 0.29 | 0.37 | 0.34 | 0.61 |
| Interest Debt Per Share | 9.07 | 8.66 | 11.72 | 10.85 | 20.94 |
| Net Debt to EBITDA | 1.37 | 1.99 | 2.12 | 2.01 | 4.16 |
| Profitability Margins | |||||
| Gross Profit Margin | 72.40% | 71.16% | 71.76% | 67.42% | 66.95% |
| EBIT Margin | 24.76% | 13.12% | 22.39% | 22.01% | 17.67% |
| EBITDA Margin | 31.84% | 21.25% | 29.95% | 29.33% | 26.26% |
| Operating Profit Margin | 25.52% | 12.82% | 22.24% | 21.94% | 17.64% |
| Pretax Profit Margin | 22.66% | 11.08% | 19.99% | 19.19% | 14.57% |
| Net Profit Margin | 17.50% | 8.21% | 16.25% | 51.00% | 17.76% |
| Continuous Operations Profit Margin | 19.25% | 9.41% | 17.50% | 16.78% | 14.24% |
| Net Income Per EBT | 77.23% | 74.06% | 81.27% | 265.74% | 121.84% |
| EBT Per EBIT | 88.76% | 86.47% | 89.90% | 87.49% | 82.60% |
| Return on Assets (ROA) | 9.37% | 4.33% | 6.55% | 24.87% | 4.09% |
| Return on Equity (ROE) | 34.96% | 18.84% | 28.96% | 141.12% | 21.50% |
| Return on Capital Employed (ROCE) | 21.03% | 10.65% | 13.95% | 17.23% | 5.80% |
| Return on Invested Capital (ROIC) | 16.61% | 8.51% | 11.37% | 13.62% | 5.32% |
| Return on Tangible Assets | 15.33% | 6.97% | 10.33% | 38.56% | 8.42% |
| Earnings Yield | 7.75% | 4.67% | 8.35% | 25.58% | 8.40% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.22 | 5.23 | 3.21 | 4.72 | 2.27 |
| Payables Turnover | 0.59 | 2.61 | 1.81 | 2.47 | 1.33 |
| Inventory Turnover | 1.52 | 1.60 | 1.22 | 1.86 | 1.04 |
| Fixed Asset Turnover | 3.26 | 3.11 | 2.39 | 3.05 | 1.71 |
| Asset Turnover | 0.54 | 0.53 | 0.40 | 0.49 | 0.23 |
| Working Capital Turnover Ratio | -7.62 | -8.06 | -11.82 | -6.66 | -5.27 |
| Cash Conversion Cycle | -295.60 | 158.82 | 210.33 | 126.30 | 236.35 |
| Days of Sales Outstanding | 86.54 | 69.79 | 113.58 | 77.40 | 160.77 |
| Days of Inventory Outstanding | 239.38 | 228.69 | 298.68 | 196.60 | 350.23 |
| Days of Payables Outstanding | 621.51 | 139.66 | 201.93 | 147.70 | 274.65 |
| Operating Cycle | 325.92 | 298.48 | 412.26 | 273.99 | 511.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.53 | 3.22 | 3.89 | 4.05 | 4.97 |
| Free Cash Flow Per Share | 2.88 | 1.75 | 3.09 | 3.35 | 3.31 |
| Dividend Paid and CapEx Coverage Ratio | 1.87 | 1.21 | 1.78 | 1.44 | 1.20 |
| Capital Expenditure Coverage Ratio | 5.42 | 2.20 | 4.83 | 5.80 | 3.00 |
| Operating Cash Flow Coverage Ratio | 0.40 | 0.39 | 0.34 | 0.39 | 0.24 |
| Operating Cash Flow to Sales Ratio | 0.22 | 0.21 | 0.26 | 0.28 | 0.32 |
| Free Cash Flow Yield | 7.90% | 6.48% | 10.60% | 11.55% | 10.15% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 12.91 | 21.45 | 11.98 | 3.91 | 11.90 |
| Price-to-Sales (P/S) Ratio | 2.26 | 1.76 | 1.95 | 1.99 | 2.11 |
| Price-to-Book (P/B) Ratio | 4.51 | 4.03 | 3.47 | 5.52 | 2.56 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 12.66 | 15.42 | 9.43 | 8.66 | 9.85 |
| Price-to-Operating Cash Flow Ratio | 10.32 | 8.41 | 7.48 | 7.17 | 6.56 |
| Price-to-Earnings Growth (PEG) Ratio | 0.10 | -0.44 | 0.00 | -0.36 | -2.45 |
| Enterprise Value Multiple | 8.46 | 10.26 | 8.62 | 8.81 | 12.20 |
| Enterprise Value | 88.02B | 68.38B | 78.26B | 75.74B | 79.12B |
| EV to EBITDA | 8.46 | 10.26 | 8.62 | 8.81 | 12.20 |
| EV to Sales | 2.69 | 2.18 | 2.58 | 2.58 | 3.20 |
| EV to Free Cash Flow | 15.11 | 19.14 | 12.51 | 11.22 | 14.93 |
| EV to Operating Cash Flow | 12.32 | 10.43 | 9.92 | 9.28 | 9.95 |
| Tangible Book Value Per Share | -3.82 | -4.62 | -5.53 | -5.60 | -16.32 |
| Shareholders’ Equity Per Share | 8.07 | 6.71 | 8.40 | 5.26 | 12.73 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.15 | 0.15 | 0.12 | 0.13 | 0.02 |
| Revenue Per Share | 16.13 | 15.39 | 14.97 | 14.57 | 15.42 |
| Net Income Per Share | 2.82 | 1.26 | 2.43 | 7.43 | 2.74 |
| Tax Burden | 0.77 | 0.74 | 0.81 | 2.66 | 1.22 |
| Interest Burden | 0.92 | 0.84 | 0.89 | 0.87 | 0.82 |
| Research & Development to Revenue | 0.23 | 0.20 | 0.21 | 0.19 | 0.20 |
| SG&A to Revenue | 0.28 | 0.35 | 0.31 | 0.29 | 0.29 |
| Stock-Based Compensation to Revenue | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 |
| Income Quality | 1.28 | 2.22 | 1.29 | 1.49 | 2.26 |
Currency in GBP